TITLE

REGIONAL: Company News Analysis

PUB. DATE
October 2003
SOURCE
Asia Monitor: South East Asia Monitor Volume 1;Oct2003, Vol. 14 Issue 10, p5
SOURCE TYPE
Country Report
DOC. TYPE
Country Report
ABSTRACT
The article reports on various developments in automotive, energy, consumer goods and pharmaceutical industries of Thailand. Japanese carmaker Suzuki is aiming to take advantage of the strong growth in the Thai motorcycle market with plans to invest THB540mn in its local motorcycle production facility. The company hopes to expand its monthly production capacity from 20,000 to 35,000 units, on the back of a 170% year-on-year rise in sales for the first seven months of 2003. The Thai subsidiary of U.S. oil company Unocal Corp. is hoping to double its current oil production level by commencing Phase 2 of its local oil development project. Randy Howard, president of Unocal Thailand Ltd., stated that the decision to go ahead with the second phase is based on the success of delineation wells and a sustained positive production performance during Phase 1 of the project. French pharmaceuticals manufacturer Sanofi-Synthelabo SA expects its revenue in Thailand to top THB1bn this year, driven by growing demand for medicines to treat atherothrombosis. According to Stephen Oldfield, general manager of Sanofi-Synthelabo Thai-land, deaths caused by atherothrombosis account for as much 52% of all disease-related deaths worldwide each year, a figure representing more than double the fatalities caused by cancer and HIV/ AIDS added together.
ACCESSION #
10947610

 

Related Articles

  • Sanofi-Synthelabo.  // Formulary;Oct2000 Resource Guide, Vol. 35 Issue 10, p88 

    Features the Sanofi-Synthelabo, a pharmaceutical manufacturer. Core areas of therapeutic research; Allocated budget for worldwide pharmaceutical research and development; Top-selling pharmaceutical products.

  • Sanofi-Synthelabo closes drug distribution centre.  // Life Science Today;Jun2000, Vol. 1 Issue 3, p4 

    Assesses the closure of drug distribution center by Sanofi-Synthelabo in France. Cause of the closure; Layoff system of the company.

  • Dream ticket to Japan.  // Life Science Today;Feb2001, Vol. 2 Issue 1, p6 

    Reports the plan of French drugmaker Sanofi-Synthelabo to expand its business in Japan.

  • MARKET BRIEFS.  // Chemical Market Reporter;01/29/2001, Vol. 259 Issue 5, p14 

    Presents news briefs from the pharmaceuticals industry as of January 29, 2001. Drug application filed by SkyePharma PLC and Sanofi-Synthelabo for Alfuzosin; Price increase made by Biddle Sawyer for all grade of metolose hydroxypropyl methylcellulose and methyl cellulose; Approval of the...

  • Plavix boom drives on sales.  // European Chemical News;7/26/2004, Vol. 81 Issue 2110, p8 

    Reports on an increase in sales of French pharmaceutical firm Sanofi-Synthélabo in the second quarter of 2004. Status of the company's Plavix anticoagulant product in the U.S. prescription drugs market; Total revenues generated from Plavix sales; Information on other high-selling drugs from...

  • News Tip: Mergers Such As Sanofi-Aventis May Actually Create Room for New Players in Pharmaceutical Market, Duke Professor Says.  // Ascribe Newswire: Medicine;5/4/2004, p47 

    Mergers like deal between pharmaceutical companies Sanofi-Synthelabo SA and Aventis SA may actually create room for the growth of smaller companies, a Duke University business professor says. Mergers have become a tool for survival among large pharmaceutical companies focused on the development...

  • Sanofi's Higher Bid for Aventis Raises Doubts.  // Chemical Market Reporter;5/3/2004, Vol. 265 Issue 18, p6 

    Reports that shares in Sanofi-Synthelabo SA dropped as investors showed doubts about the prospects for the company's merger with its rival Aventis SA to create a market leader in European pharmaceuticals. Inhibition of foreign investment; Terms of the deal; Patent risks for Sanofi-Aventis' drugs.

  • News Tip: Mergers Such As Sanofi-Aventis May Actually Create Room for New Players in Pharmaceutical Market, Duke Professor Says.  // Ascribe Newswire: Medicine;4/27/2004, p103 

    Mergers like Monday's deal between pharmaceutical companies Sanofi-Synthelabo SA and Aventis SA may actually create room for the growth of smaller companies, a Duke University business professor says. Mergers have become a tool for survival among large pharmaceutical companies focused on the...

  • Meeting Expectations. Shalo, Sibyl // Pharmaceutical Executive;Apr2004 Supplement, Vol. 24, p20 

    Delves into product launches of the company Sanofi-Synthélabo SA in the U.S. Similarity between planning a sales force product launch meeting and planning a wedding; Pressure on companies to make launch meetings exciting and memorable for sales representatives (or reps); Identification of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics